- Home
- GSHD vs XERS Comparison
GSHD vs XERS Comparison
Compare GSHD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | XERS |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 891.2M | 1.0B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GSHD | XERS |
|---|---|---|
| Price | $41.85 | $6.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $72.50 | $10.83 |
| AVG Volume (30 Days) | 365.4K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 1.04 | 0.01 |
| Revenue | ★ $365,304,000.00 | $49,590,000.00 |
| Revenue This Year | $16.40 | $34.37 |
| Revenue Next Year | $18.53 | $22.86 |
| P/E Ratio | ★ $36.30 | $626.50 |
| Revenue Growth | 16.15 | ★ 142.67 |
| 52 Week Low | $35.84 | $4.30 |
| 52 Week High | $113.00 | $10.08 |
Technical Indicators
Market Signals| Indicator | GSHD | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 45.48 |
| Support Level | $39.99 | $5.79 |
| Resistance Level | $46.40 | $7.14 |
| Average True Range (ATR) | 2.44 | 0.30 |
| MACD | -0.40 | -0.02 |
| Stochastic Oscillator | 44.26 | 4.33 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.